The plan proposes incentives and penalties to induce more resilient sourcing, but does not promote testing to help purchasers identify high-quality manufacturers.
While the Biden administration and US Congress continue to debate ways to address perceived prescription drug pricing concerns, the Food and Drug Administration (FDA) is taking action.
While the Biden administration and US Congress continue to debate ways to address perceived prescription drug pricing concerns, the Food and Drug Administration (FDA) is taking action..